← Back to Search

Monoclonal Antibodies

BMS-986278 for Pulmonary Fibrosis

Massachusetts General Hospital, Boston, MA
BMS-986278 +1 morePhase 3RecruitingResearch Sponsored by Bristol-Myers Squibb

Study Summary

This trial will test a drug to see if it's safe and effective to treat a lung disease called Idiopathic Pulmonary Fibrosis.

Eligible Conditions
  • Idiopathic Pulmonary Fibrosis

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You have been diagnosed with idiopathic pulmonary fibrosis within the last seven years, as evidenced by a chest CT scan and confirmation of usual interstitial pneumonia.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at week 52 and up to approximately 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and at week 52 and up to approximately 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Absolute change from baseline in forced vital capacity (FVC) measured in mL
Secondary outcome measures
Change from baseline in EQ-5D-5L visual analog scale score
Change from baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) health utility index score
Change from baseline in L-PF dyspnea domain score
+26 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: BMS-986278 Dose 2Experimental Treatment1 Intervention
Group II: BMS-986278 Dose 1Experimental Treatment1 Intervention
Group III: BMS-986278 PlaceboPlacebo Group1 Intervention
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 2

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,603 Previous Clinical Trials
4,047,086 Total Patients Enrolled
3 Trials studying Idiopathic Pulmonary Fibrosis
361 Patients Enrolled for Idiopathic Pulmonary Fibrosis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you please detail the safety profile of BMS-986278 Dose 1?

"Based on the available data, our team at Power has assessed BMS-986278 Dose 1's safety to be 3 out of a possible score range from 1 to 3. This score is due to multiple rounds of clinical testing demonstrating efficacy and supporting evidence for its security profile."

Answered by AI

How many centers are overseeing this clinical trial?

"At the moment, this medical trial is being conducted in 443 sites across the United States. These include Jasper, Phoenix and La Jolla, with a variety of other locations available to choose from. Choosing an institution close to you can help reduce any associated travelling costs that may be incurred when enrolling in the study."

Answered by AI

Are there still openings available for the trial participants?

"Per information hosted on clinicaltrials.gov, this experiment is not presently enrolling participants. The trial was first published on August 16th 2023 and last edited a day later; however, there are currently 434 alternative trials actively seeking volunteers."

Answered by AI

Who else is applying?

What site did they apply to?
University of Kansas Medical Center (KUMC)
Accellacare US Inc. of Wilmington
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?

Why did patients apply to this trial?

i have covid fibrosis with significantly compromised lung function. covid onset was 11/20 and my ku pulmonologist is mark hamblin.
PatientReceived 2+ prior treatments
~790 spots leftby Oct 2026